Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 4:28 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 4:28 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.
Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.
Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.
Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise
by Zacks Equity Research
Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.
DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.
Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View
by Zacks Equity Research
Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low
by Zacks Equity Research
Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.
Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.
Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
by Zacks Equity Research
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.
Cerner (CERN) Meets Q1 Earnings Estimates, Lowers '18 View
by Zacks Equity Research
Lower revenues stemming from lesser-than-expected subscription bookings hurt Cerner's (CERN) Q1 results.
Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.
CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow
by Zacks Equity Research
CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.
AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.
Ecolab (ECL) Q1 Earnings & Revenues Top, '18 Guidance Solid
by Zacks Equity Research
Solid performance in Global Industrial and Global Institutional segments gave a boost to Ecolab's (ECL) earnings and revenues in Q1.
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up
by Zacks Equity Research
Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.
Hill-Rom (HRC) Earnings & Revenues Beat in Q2, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q2.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.